189747-29-3

Upstream product

• 54368-61-5 ethyl 2,4-dichloro-5-nitro-6-pyrimidinecarboxylic acid 
• 52047-16-2 ethyl 5-nitro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylate 
• 17687-24-0 5-nitroorotic acid 
• 65-86-1 orotic acid 
• 59950-50-4 ethyl 5-amino-2-chloropyrimidine-4-carboxylate 

Downstream Products

• 189747-31-7 6-chloropyrimido[5,4-d]pyrimidin-4(3H)-one 
• 189747-34-0 2,8-dichloropyrimido(5,4-d)pyrimidine 
• 189747-37-3 6-chloro-4-(phenylamino)pyrimido[5,4-d]pyrimidine 
• 189747-55-5 4-[(3-methylphenyl)amino]-6-chloropyrimido[5,4-d]pyrimidine 
• 189747-43-1 4-[(3-bromophenyl)amino]-6-chloropyrimido[5,4-d]pyrimidine 

Relevant academic research and scientific papers

NITROGEN HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present disclosure relates to compounds of formula (I): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, and methods of using the compounds as inhibitors of receptor tyrosine kinases, in particular oncogenic mutants of ErbB-receptors e.g. in the treatment of cancer.

PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS

Compounds of the general formula(I): (I) processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor

A series of 6-substituted 4-anilinopyrimido[5,4-d]pyrimidines has been prepared and shown to be potent inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR). These compounds are structurally related to the pyrido[3,2-d]